Keefer to retire from JJVC after 23 years

Article

Jacksonville, FL—After a 23-year career with Johnson & Johnson Vision Care (JJVC), and over 40 years in eye care, Phil Keefer has announced his decision to retire, effective Sept. 1.

Jacksonville, FL-After a 23-year career with Johnson & Johnson Vision Care (JJVC), and over 40 years in the eye care, Phil Keefer has announced his decision to retire, effective Sept. 1.

Keefer joined JJVC in 1989 as executive vice president sales, marketing, professional affairs and strategic planning, where he oversaw the initial launch of the Acuvue brand. In 1993, Keefer was appointed vice president, new business development, where he created and implemented global strategic plans that included the international expansion of the vision care franchise. He served as managing director/president of multiple regions, including Asia Pacific, the Americas, Latin America, and Japan.

Keefer is currently president of The Vision Care Institute, where he conceived and implemented a professional education strategy that resulted in the creation of 15 Vision Care Institutes and 9 satellite centers around the world. He has also served as an active member of the JJVC Global Management Board for his entire 23-year career.

In addition to his job responsibilities, Keefer was chairman of the Contact Lens Institute Board of Governors, and has also served on several boards, including the American Optometric Foundation, VisionWeb Inc., the National Boards of The Vision Council of America and Prevent Blindness America, and the Florida Board of Prevent Blindness America. In 2009, The American Academy of Optometry presented him with the Honorary Fellowship Award for his distinguished contributions to the science and art of optometry.

Before joining Johnson & Johnson in 1989, Keefer held positions at Allergan, CooperVision, Optical Radiation Corporation, and Polymer Technology, where he was instrumental in taking the company from start up to global distribution and worldwide success.

For more articles in this issue of InDispensable, click here.

Recent Videos
Optometrists reflect on their residency experiences and provide advice to current residents.
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Bonnie An Henderson, MD, the cofounder and program director of EnVision Summit
What was the biggest innovation in eye care in 2024?
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
© 2024 MJH Life Sciences

All rights reserved.